Nimodipine in subcortical vascular dementia trial

Alzheimer Disease and Associated Disorders

Volumn 13, Issue SUPPL. 3, 1999, Pages

  Rossi, Ruggero ^a   Inzitari, Domenico ^b   Pantoni, Leonardo ^b   Del Ser, Teodoro ^c   Erkinjuntti, Timo ^d   Wallin, Anders ^e   Bianchi, Cosetta ^a   Badenas, Josep M ^f   Beneke, Manfred ^g  

^a Bayer SpA Italy   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Hospital de Leganes   (Spain)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f Bayer SA   (Spain)

^g Bayer Vital GmbH   (Germany)

Author keywords

Clinical trial; Methodology; Nimodipine; Protocol design; Subcortical vascular dementia

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; NIMODIPINE;

AGED; ARTICLE; BRAIN CORTEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; INTERNATIONAL COOPERATION; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; RANDOMIZED CONTROLLED TRIAL; VASCULARIZATION;

AGED; AGED, 80 AND OVER; CALCIUM CHANNEL BLOCKERS; CEREBRAL CORTEX; DEMENTIA, VASCULAR; DOUBLE-BLIND METHOD; HUMANS; INTERNATIONAL COOPERATION; MIDDLE AGED; NIMODIPINE; RESEARCH DESIGN;

EID: 0033202574     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199912003-00023     Document Type: Article

References (59)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed, rev. Washington, DC: APA Press, 1987.
2. Auer LM, Oberbauer RM, Schalk HV Human pial vascular reaction to intravenous nimodipine infusion during EC-IC bypass surgery. Stroke 1983;14:210-21.
3. Blennow k, Wallin A, Uhlemann C, Gottfries CG. White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand 1991;83:187-93.
4. Breteler MMB, van Amerongen NM, van Swieten JC, et al. Cognitive correlates of ventricular enlargement and cerebral white matter lesions on magnetic resonance imaging. The Rotterdam Study. Stroke 1994;25:1109-15.
5. Brun A. Pathology and pathophysiology of cerebrovascular dementia: pure subgroups of obstructive and hypoperfusive etiology. Dementia 1994;5:145-7.
6. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986;19:253-62.
7. Brunner C, Spiegel R. Eine Validierungsstudie mit der NOSGER (Nurses' Observation Scale for Geriatric Patients), einem neuen Beurteilungsinstrument fuer die Psychogeriatrie. Zeitsch Klin Psychol 1990;19:211-29.
8. Cummings JL. Vascular subcortical dementias: clinical aspects. Dementia 1994;5:177-80.
9. De Jong GI, Traber J, Luiten PGM. Formation of cerebrovascular anomalies in the ageing rats is delayed by chronic nimodipine application. Mech Ageing Dev 1992;64:255-72.
10. Dorsch NW, Branston NM, Harris RJ, Bentivoglio P, Symon L. An experimental study of the effect of nimodipine in primate subarachnoid hemorrhage. Acta Neurochir 1989;99:65-75.
11. Erkinjuntti T, Gao F, Lee DH, Eliasziw M, Merskey H, Hachinski VC. Lack of difference in brain hyperintensities between patients with early Alzheimer's disease and control subjects. Arch Neurol 1994;51:260-8.
12. Esiri MM, Wilcock GK, Morris JH. Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997;63:749-53.
13. Fieschi C, Argentine C, Toni D, Pozzilli C. Calcium antagonists in ischemic stroke. J Cardiovasc Pharmacol 1988;12(suppl 6):S83-5.
14. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
15. Garcia JH, Brown GG. Vascular dementia: neuropathological alterations and metabolic brain changes. J Neurol Sci 1992;109:121-31.
16. Gold G, Giannakopoulos P, Montes-Paixao C Jr, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology 1997;49:690-4.
17. Greenberg JH, Uematsu D, Araki N, Hickey WF, Reivich M. Cytosolic free calcium during focal cerebral ischemia and the effects of nimodipine on calcium and histologic damage. Stroke 1990;21(suppl IV):IV72-7.
18. Guy W. CGI - Clinical Global Impressions. In: ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976:217-22.
19. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-7.
20. Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neurol 1987;44:21-3.
21. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
22. Inzitari D, Di Carlo AS, Mascalchi M, Pracucci G, Amaducci L. The cardiovascular outcome of patients with motor impairment and extensive leuko-araiosis. Arch Neurol 1995;52:687-91.
23. Isaacs B, Kennie AT. The set test as an aid to the detection of dementia in old people. Br J Psychiatry 1973;123:467-70.
24. Itil TM, Itil KZ. The comparative CNS: Pharmacology of nimodipine in humans. In: Betz E, Deck K, Hoffmeister F, eds. Nimodipine: pharmacological and clinical properties. Stuttgart, Germany: Schattauer FK, 1985:185-202.
25. Jan M, Buchheit F, Tremoulet M. Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. Neurosurgery 1988;23:154-7.
26. Jansen I, Tfelt-Hansen P, Edvinsson L. Comparison of the calcium entry blockers nimodipine and flunarizine on human cerebral and temporal arteries: role in cerebrovascular disorders. Eur J Clin Pharmacol 1991;40:7-15.
27. Konno S, Meyer JS, Terayama Y, Margishvili GM, Mortel KF. Classification, diagnosis and treatment of vascular dementia. Drug Aging 1997;11:361-73.
28. Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in cerebrovascular disease. Drugs 1989;37:669-99.
29. Loeb C. Vascular dementia. Dementia 1990;1:175-84.
30. Lopez OL, Becker JT, Jungreis CA et al. Computed tomography - but not magnetic resonance imaging-identified periventricular white-matter lesions predict symptomatic cerebrovascular disease in probable Alzheimer disease. Arch Neurol 1995;52:659-64.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
32. Mee E, Dorrance D, Lowe D, Neil-Dwyer G. Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage. Neurosurgery 1988;22:484-91.
33. Menazzi D, Montenegro R, Castro JM. Nimodipine in the treatment of chronic cerebrovascular insufficiency. In: Betz E, Deck K, Hoffmeister F, eds. Nimodipine: pharmacological and clinical properties. Stuttgart, Germany: Schattauer FK, 1985:334-44.
34. Meyer JS, Kawamura J, Terayama Y. White matter lesions in the elderly. J Neurol Sci 1994;110:1-7.
35. Nevitt MC, Cummings SR, Kidd S, Black D. Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA 1989;261:2663-8.
36. Ohman J, Heiskanen O. Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 1988;69:683-6.
37. Oswald WD, Fleishman UM. Nuernberger-Alters-Inventar NAI. Erlangen, Germany: Oswald WD and Fleishman UM, 1986.
38. Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 1996a;19:497-506.
39. Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. Stroke 1995;26: 1293-301.
40. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997;28:652-9.
41. Pantoni L, Garcia JH, Brown GG. Vascular pathology in three cases of progressive cognitive deterioration. J Neurol Sci 1996b;135:131-9.
42. Pantoni L, Inzitari D, Pracucci G, et al. Cerebrospinal fluid proteins in patients with leucoaraiosis: possible abnormalities in blood-brain barrier function. J Neurol Sci 1993;115:125-31.
43. Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988;68:505-17.
44. Reisberg B, Ferris SH, deLeon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychialry 1982;139:1136-9.
45. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
46. Schmage N, Bergener M. Global rating, symptoms, behaviour, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes. Int Psychogeriatr 1992;4(suppl 1):89-99.
47. Scriabine A, Schuurman T, Traber J. Pharmacological basis for the use of nimodipine in central nervous system disorders. FASEB J 1989;3: 1799-806.
48. Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment-Geriatric (SCAG). J Am Geriatr Soc 1974;22:107-13.
49. Takayasu M, Basset JE, Dacey RG. Effects of calcium antagonists on intracerebral penetrating arterioles in rats. J Neurosurg 1988;69:104-9.
50. Tobares N, Pedromingo A, Bigorra J. Nimodipine treatment improves cognitive function in vascular dementia. In: Bergener M, Reisberg B, eds. Diagnosis and treatment of senile dementia. Berlin: Springer-Verlag, 1989:360-5.
51. Van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry 1990;53:1080-3.
52. Wallin A, Blennow K. Heterogeneity of vascular dementia: mechanisms and subgroups. J Geriatr Psychiatry Neurol 1993;6:177-88.
53. Wallin A, Blennow K, Gottfries CG. Subcortical symptoms predominate in vascular dementia. Int J Geriatr Psychiatry 1991;6:137-46.
54. Wechsler D. A standardized memory scale for clinical use. J Psychol 1945;19:87-95.
55. Welsch M, Nuglisch J, Krieglstein J. Neuroprotective effect of nimodipine is not mediated by increased cerebral blood flow after transient forebrain ischemia in rats. Stroke 1990;21(suppl IV):IV105-7.
56. Wetterling T, Kanitz RD, Borgis KJ. Clinical evaluation of the ICD-10 criteria for vascular dementia. Eur Arch Psychiatry Clin Neurosci 1993;243:33-40.
57. Wetterling T, Kanitz RD, Borgis KJ. The ICD-10 criteria for vascular dementia. Dementia 1994;5:185-8.
58. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 1990;9:65-72.
59. World Health Organization. International statistical classification of diseases, 10th revision (ICD-10). Geneva, Switzerland: WHO, 1992.